Such interventions would have the potential to reduce the prevalence of chronic pain in the population .
Although certain risk factors can identify individuals who are most likely to develop chronic pain , few interventions to prevent chronic pain have been identified .
To facilitate the identification of preventive interventions , an IMMPACT meeting was convened to discuss research design considerations for clinical trials investigating the prevention of chronic pain .
We present general design considerations for prevention trials in population s that are at relatively high risk for developing chronic pain .
A pilot study on the influence of a corticotropin (4-9) analogue on Vinca alkaloid-induced neuropathy.
In a r and omized , double-blind , placebo-controlled pilot study , we examined the effect of Org 2766 - -a corticotropin ( 4 - 9 ) analogue -- on neurotoxicity  in 28 patients with lymphoma who were treated with combination chemotherapy containing Vinca alkaloids ( vincristine and vinblastine ) .  The patients received a total dose of 12 mg of vincristine in the case of non-Hodgkin 's lymphoma and a total dose of 16 mg of vincristine in the case of Hodgkin 's disease . Moreover , the patients with Hodgkin 's disease received a mean total dose of 84 mg of vinblastine . Subcutaneous injections of 2 mg of Org 2766 or placebo were administered to patients with non-Hodgkin 's lymphoma on days 1 and 10 of each chemotherapy course and to patients with Hodgkin 's disease on days 1 and 8 of each chemotherapy course . The first injection was always given before the administration of vincristine .  Assessment of neurologic symptoms and signs and measurement of sensory thresholds ( vibration sense and temperature sense ) were performed on day 1 of the first , fourth , and sixth ( or eighth ) courses and 6 weeks after cessation of chemotherapy . Thirteen patients ( mean age , 44.7 years ) received  Org 2766 and 15 patients ( mean age , 54.7 years ) received placebo . More symptoms occurred in the placebo group , but only numbness and autonomic complaints occurred significantly more often in the placebo group . Motor deficit and sensory disturbances were more severe and also occurred significantly more often in the placebo group . There was no difference with respect to reflex examination findings and sensory thresholds . ( ABSTRACT TRUNCATED AT 250 WORDS
Such interventions would have the potential to reduce the prevalence of chronic pain in the population .
Although certain risk factors can identify individuals who are most likely to develop chronic pain , few interventions to prevent chronic pain have been identified .
To facilitate the identification of preventive interventions , an IMMPACT meeting was convened to discuss research design considerations for clinical trials investigating the prevention of chronic pain .
We present general design considerations for prevention trials in population s that are at relatively high risk for developing chronic pain .